In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

A longer prednisolone tapering period is better than a shorter one at improving the rate of clinical remission in patients with moderate-to-severe ulcerative colitis.

p #60; 0.001. Data from [74]. Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib's ...

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon driven by an abnormal immune response. It typically begins in the rectum and spreads continuously, occasionally involving a cecal ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...

Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, ...

Northwestern Medicine investigators have identified a surprising culprit in the progression of inflammatory bowel disease: a naturally occurring metabolic compound in the gut, according to a study ...